Selected partnerships
| Partner | Scope |
|---|---|
| Avid Radiopharmaceuticals | Radiopharmaceutical compounds |
| Bausch & Lomb | Selective glucocorticoid receptor Agonist (SEGRA) for treatment of eye diseases * |
| BioInvent | Antibody discovery |
| Boehringer Ingelheim | Co-marketing of telmisartan in Europe, a compound for management of hypertension |
| Eidgenössische Technische Hochschule Zürich(ETH) | Radiopharmaceutical compounds |
| Genentech | Development rFVIII worldwide for treatment of hemophilia |
| Genzyme Corporation | Campath® in chronic lymphocytic leukemia and multiple sclerosis |
| GlaxoSmithKline | Co-promotion of Levitra® in the US * |
| ImmunoGen | Antibody toxin conjugates |
| Indevus Pharmaceuticals | Development of Nebido® in the US for treatment of male hypogonadism * |
| Johnson & Johnson | Development of novel anticoagulant rivaroxaban (Xarelto®) and distribution in the US * |
| Nektar Therapeutics | Development of targeted inhaled antibiotic therapy for pulmonary infections (Amikacin Inhale and Cipro Inhale) |
| Onyx Pharmaceuticals | Co-development of Nexavar® for various cancer indications |
| Pfizer | Development of DGAT-1 inhibitor for treatment of diabetes and obesity * |
| Philogen | Development of immunoconjugates for cancer therapy and diagnosis |
| Regeneron Pharmaceuticals | Development of VEGF Trap-Eye for the treatment of eye diseases |
| Seattle Genetics | Antibody toxin conjugates |
| Schering-Plough | Distribution of Primary Care products in the US * |
| Shire | Development of Fosrenol® in Japan for treatment of hyperphosphatemia |
| Stanford University | Radiopharmaceutical compounds |
| ZymoGenetics | Recombinant thrombin |
| * = substance/product has been outlicensed by Bayer Schering Pharma | |
Font size
click to adjust
Page tools
- Add to info basket
- Black-and-white version
- Text version
- Printer friendly version
- Bookmark this page